![]() |
市場調查報告書
商品編碼
1304546
全球高壓氧治療市場 - 2023-2030年Global Hyperbaric Oxygen Therapy Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球高壓氧治療市場規模在2022年達到32億美元,預計到2030年將達到67億美元,實現利潤豐厚的成長。在預測期內(2023-2030年),全球高壓氧治療市場預計將呈現9.9%的複合年成長率。技術的不斷進步和對新型產品投資的不斷成長推動了高壓氧治療市場需求的發展趨勢。
高壓氧治療是動脈氣體栓塞和減壓病的唯一公認治療方法。正如波義耳定律所預測的那樣,在加壓過程中(也稱為高壓氧治療的壓縮階段),體內含氣腔會發生收縮,這有助於減少氣泡並緩解組織或血管內區域的壓力。新產品的推出和傷口癒合率的上升是推動全球高壓氧治療市場發展的主要因素。
高壓氧療法的市場範圍包括糖尿病足潰瘍、傷口癒合、減壓病、感染治療、氣體栓塞等應用,這增加了高壓氧療法的市場佔有率。全球高壓氧治療市場正在不斷擴大,其原因包括各國不斷加大研發力度,即將批准的新型產品也為高壓氧治療市場的成長創造了積極的前景。
高壓氧療法利用道爾頓定律和亨利定律分別提高肺泡-血漿梯度和氧溶解度。用數學方法來說明這一點,在3 ATA下給予100%的氧氣,可使組織和動脈血氧張力分別提高500和2000 mmHg,從而可提供6 mL O2/dL。
顯而易見,HBOT後,血漿攜帶溶解氧的能力足以在沒有血紅蛋白輔助的情況下維持體內平衡。因此,即使在血紅蛋白氧運輸受阻的情況下,如一氧化碳中毒和嚴重貧血,血漿中的氧仍可輸送到組織中。
與血紅蛋白相比,使用血漿輸送氧氣的另一個好處是,血漿可以到達紅細胞因物理障礙(如血栓或閉塞)而無法到達的地方。這些優勢是推動高壓氧治療市場成長的主要因素。
高壓氧的潛在臨床益處正在許多不同的領域得到研究。研究範圍包括老年病和中風。此外,還對運動損傷、高原病、腦損傷、認知功能、偏頭痛、暴發性肝炎、脊髓損傷、閉合性顱腦損傷和鐮狀細胞危象進行了研究。
世界各地的多中心研究人員還在研究暴發性紫癜、放線菌病、腸系膜病、血栓形成、視網膜中央動脈閉塞、囊樣黃斑水腫和麻風病。隨機臨床試驗設計、安慰劑效應、霍桑效應、藥代動力學和其他主題也在討論之中。
由於縮短了住院時間和病程,成本分析表明,在常規治療的基礎上增加高壓氧可顯著節約成本。目前正在進行各種研究。
與所有醫療程序類似,高壓氧治療有利有弊。高濃度氧可導致氧化應激,從而損害細胞和組織,包括DNA。如果損傷未得到充分癒合,這有可能導致癌症,因為它會導致突變。然而,對科學文獻的研究表明,儘管存在這種擔憂,但絕大多數已發表的研究都沒有發現這種影響。
快速的壓力變化可導致中耳、顱竇或(極少數情況下)牙齒或肺部破裂,給患者帶來輕微至劇烈的疼痛。通過對患者進行降低風險技術(如自動充氣技術)的教育,可以避免這種情況的發生。儘管HBOT可治療的疾病和失調範圍不斷擴大,但在美國仍存在一些限制。
一次90分鐘的療程一般在300至400美元之間,因此HBOT的價格相當昂貴。因此,30-40次治療的價格在9,000-16,000美元之間。然而,與院內非高壓氧治療相比,對患有骨壞死的患者進行高壓氧治療的經濟分析表明可節省96,000美元。
COVID-19疫情和全球封鎖對各行各業的企業財務健康都產生了影響。因此,美國食品和藥物管理局(FDA)發布了COVID-19衛生緊急狀態期間的指導方針,其中包括協助申辦者和研究人員、確保試驗參與者安全、遵循良好臨床實踐(GCP)以及降低試驗完整性風險的一般注意事項。
據估計,俄烏衝突對全球高壓氧治療市場的影響較小,因為該地區的主要市場參與者較少。然而,原料進出口的影響預計在預測期內對全球高壓氧治療市場的成長影響不大。
The Global Hyperbaric Oxygen Therapy Market size reached US$ 3.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 6.7 billion by 2030. The global hyperbaric oxygen therapy market is expected to exhibit a CAGR of 9.9% during the forecast period (2023-2030). The increasing technological advancements and the growing investments in novel products are driving up demand for hyperbaric oxygen therapy market trends.
The only accepted treatment for arterial gas embolism and decompression sickness is HBOT. As predicted by Boyle's law, a contraction takes place in the body's gas-containing cavities during pressurization, also referred to as the compression phase of HBOT, which aids in reducing air bubbles and relieving pressure in the tissue or intravascular area. The launch of new products and an increase in the prevalence of wound healing are the main factors propelling the global market for hyperbaric oxygen therapy.
The hyperbaric oxygen therapy market scope comprises applications such as diabetic foot ulcers, wound healing, decompression sickness, infection treatment, gas embolism and others, which has increased the hyperbaric oxygen therapy market share. The global market for hyperbaric oxygen therapy is expanding as a result of factors including increasing research and development and their upcoming novel product approvals across countries are also creating a positive outlook for the hyperbaric oxygen therapy market growth.
Dalton's law and Henry's law are both utilized by hyperbaric oxygen therapy to boost the alveoli-plasma gradient and oxygen solubility, respectively. To illustrate this mathematically, giving 100% oxygen at 3 ATA raises tissue and arterial oxygen tension by 500 and 2000 mmHg, respectively, allowing for the delivery of 6 mL O2/dL.
Evidently, after HBOT, the plasma's ability to carry dissolved oxygen is sufficient to sustain homeostasis without the aid of hemoglobin. As a result, even in conditions where hemoglobin oxygen transport is impeded, like carbon monoxide poisoning and severe anemia, this oxygen can still be delivered to tissues.
Another benefit of employing plasma to deliver oxygen over hemoglobin is that it can get to places where red blood cells can't because of physical obstructions (such clots or occlusions). These advantages are the major factor that will help in driving the growth of the hyperbaric oxygen therapy market.
The potential clinical benefits of hyperbaric oxygen are being investigated in a number of different contexts. Investigated are senility and strokes. Research is also being done on sports injuries, high altitude sickness, brain injuries, cognitive functions, migraines, fulminant hepatitis, Spinal cord injury, closed head injury, and sickle cell crisis.
Workers in multicentric studies around the world are also investigating purpura fulminans, actinomycosis, mesenteric, thrombosis, central retinal artery occlusion, cystoid macular edema, and leprosy. Randomized clinical trial designs, the placebo effect, the Hawthorne effect, pharmacokinetics, and other topics are also being discussed.
Due to shorter hospital stays and shorter illness duration, cost analysis has demonstrated that adding hyperbaric oxygen to conventional treatment yields significant cost savings. Various kinds of research are being done.
Similar to every medical procedure, treatment has advantages and disadvantages. High oxygen concentrations can lead to oxidative stress, which can damage cells and tissues, including DNA. This has the potential to cause cancer if the damage is not sufficiently healed since it can result in mutations. An examination of the scientific literature, however, revealed that, in spite of this worry, the vast majority of published investigations had failed to find such an effect.
Rapid pressure shifts can cause the middle ear, cranial sinuses, or (rarely) the teeth or lungs to rupture, causing mild to severe pain in the patient. By educating the patient about risk reduction techniques like the auto inflation technique, this can be prevented. Despite the expanding range of illnesses and disorders that HBOT can treat, there are still some restrictions in place in the United States.
With a typical 90-minute session ranging between $300 and $400, HBOT is rather pricey. Therefore, the price of 30-40 sessions can range from $9,000-16,000. However, compared to in-hospital, nonhyperbaric oxygen therapy, an economic analysis of hyperbaric oxygen therapy for individuals with osteoradionecrosis revealed a savings of $96,000.
The COVID-19 epidemic and the worldwide lockdown have had an effect on the financial health of businesses in all industries. As a result, the U.S. Food and Drug Administration (FDA) released guidelines for the duration of the COVID-19 health emergency that include general considerations to assist sponsors and researchers, ensure trial participants' safety, follow good clinical practice (GCP), and reduce risks to trial integrity.
The Russia-Ukraine conflict is estimated to have a low impact on the global hyperbaric oxygen therapy market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global hyperbaric oxygen therapy market growth over the forecast period.
The global hyperbaric oxygen therapy market is segmented based on product type, application, end user and region.
Hemostasis, the elimination of infectious agents, the resolution of the inflammatory response, the development of a connective tissue matrix, and resurfacing are all stages of the normal wound healing process, which is a positive feedback system. Chronic wounds are ones that do not fully heal as a result of an internal or external issue that arises throughout one or more stages of the healing process.
These include arterial ulcers, pressure ulcers, venous stasis ulcers, and diabetic wounds. The most frequent causes of wound healing delays are infection and ischemia, both of which are characterized by hypoxia. The infection triggers an overly aggressive response during the inflammatory stage of wound healing, which leads to a quick loss of oxygen in the tissue and inadequate blood flow because of edema.
By boosting the blood's oxygen content and creating a conducive gradient for oxygen diffusion into the injured tissues, hyperbaric oxygen therapy promotes the healing process. Since fibroblast proliferation, angiogenesis, collagen synthesis, and infection resistance are oxygen-dependent activities, enough oxygen is crucial for healing. HBOT has also been demonstrated to control inflammation by generating reactive oxygen species.
Manufacturers have chances to expand their operations in this region because of the rising demand for hyperbaric oxygen therapy for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised the industrial production of hyperbaric oxygen chambers, which has increased the demand.
There are many manufacturers and suppliers in North America, and as a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for research and development of novel products.
The market will grow as new technology for research and development emerge. Rising technological developments, governmental approvals, and the introduction of new products all contribute to growth. People are becoming more aware of novel wound healing therapies or chambers, leading to the expansion of the market in this region. These factors are responsible for dominance of North America.
The major global players in the hyperbaric oxygen therapy market include: Environmental Tectonics Corporation, Sosgroup, HEARMEC, Gulf Coast Hyperbarics Inc., Tekna Hyperbaric, Perry Baromedical, Hpotech Hyperbaric Solutions, Haux Life Support, Sechrist Industries, Inc and Royal IHC among others.
The global hyperbaric oxygen therapy market report would provide approximately 53 tables, 54 figures and 195 Pages.
Australia
LIST NOT EXHAUSTIVE